A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

This trial is testing JNJ-89853413 — a new targeted therapy — in people with acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) that have relapsed (come back) or are refractory (not responding) to prior treatments. Both are serious blood cancers where the bone marrow produces abnormal cells. **You may be eligible if...** - You have been diagnosed with relapsed or refractory AML or moderate-high to very high risk MDS per WHO 2022 criteria - You weigh at least 40 kg - You are in reasonably good health (ECOG score 0–2) - Your kidneys are functioning adequately (eGFR ≥ 40 mL/min) - Your blood test results are within the required ranges **You may NOT be eligible if...** - You have significant lung problems or breathing difficulties - You have uncontrolled infections or certain other serious health conditions - Your kidney or other organ function does not meet the study requirements Talk to your doctor to see if this trial is right for you.